NCT04658147 is evaluating Relatlimab, an anti-LAG-3 monoclonal antibody, among patients with HCC, while NCT03849469 is assessing the utility of a bispecific antibody (an antibody capable of binding two receptors at once) that targets both CTLA-4 and LAG-3. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.